Karius

23 articles about Karius

• Karius and eGenesis partner to help accelerate xenotransplantation for patients in need of organ transplants

  4/11/2023

  Karius® and eGenesis, Inc. a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced a partnership through which the two companies will develop infectious disease diagnostics for xenotransplantation initially from porcine to primates and ultimately to humans. 

• Karius Prepares for Further Growth with New Chief Financial Officer, Chief Legal Officer Appointments

  12/9/2021

  Karius, the world leader in liquid biopsy for infectious diseases, announced the addition of two key executives to best position the company for continued growth.

• Karius receives New York State permit for its liquid biopsy test to detect infectious diseases

  8/17/2021

  Karius has received approval from the New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP) for its Karius Test for pathogen detection.

• Karius Strengthens Leadership Team, Names Former CDC Exec as Chief Medical Officer

  5/27/2021

  Leading authority on infectious disease, Dr. Bradley Perkins, to accelerate clinical evidence of the Karius Test™, a liquid biopsy for infectious disease

• Karius Launches Multicenter Study to Evaluate the Diagnostic Value of the Karius Test for Pneumonia in Immunocompromised Patients

  8/3/2020

  Karius, the world leader in liquid biopsy for infectious diseases, announced today active enrollment in a multicenter, prospective study that will evaluate the diagnostic value of the Karius ® Test for pneumonia in immunocompromised adult patients including those with hematological cancers. The Karius Test is a non-invasive bloo

• 

  Karius Raises $165 Million to Advance Infectious Disease Liquid Biopsy Tech

  2/24/2020

  “This transformative round will allow Karius to help more patients faster, fuel the next wave of clinical studies and accelerate technology innovation,” said Karius’ chief executive officer Mickey Kertesz.

• Karius Test® Demonstrates Ability To Detect Pathogens Standard Tests Can Miss In Pneumonia Cases

  10/2/2019

  Karius will present six studies at IDWeek™ 2019 highlighting the clinical utility of the Karius Test.

• Study Validates Karius Test to Identify Life-Threatening Infections

  2/11/2019

   Karius, a life sciences company, announced today that the peer-reviewed journal Nature Microbiology published a study validating the Karius® Test for detecting pathogens and showing that the test identifies pathogens potentially faster than standard testing.  

• 

  Is There a Diagnostic Company to Rise From the Ashes of Theranos?

  1/30/2019

  Companies are filling in the gaps and the entire area of so-called “liquid biopsies” is hot these days, with companies like Guardant Health, Karius, Freenome, Apostle and GRAIL Bio entering the market. With this backdrop, let’s look at some companies working in the same field as the now-defunct T...

• Karius and Dasa enter into a partnership to introduce the Karius Test into Brazil

  10/29/2018

  Karius, a life sciences company transforming infectious disease diagnostics with genomics, is forming a partnership with Dasa, the largest medical diagnostic company in Latin America, effective October 19, 2018.

• Karius and Dasa enter into a partnership to introduce the Karius Test into Brazil

  10/26/2018

  The quantitative next-generation sequencing blood test for infectious diseases makes an international impact

• 

  Investor Enthusiasm About Liquid Biopsies Drives Guardant Health IPO to $1.59 Billion Valuation

  10/5/2018

  Guardant Health went on the Nasdaq yesterday under the symbol GH. Shares climbed almost 70 percent on the first day of trading, selling 12.5 million shares at $19 per share in the initial public offering (IPO).

• Karius Announces Winners of the 2018 Clinical Investigator Awards

  10/1/2018

  Karius today announced the winners for its 2018 Clinical Investigator Awards for Applied Infectious Disease Genomics.

• 

  As Liquid Biopsies Grow, Who's Going to Pay?

  9/20/2018

  Ilan Danieli, chief executive officer and co-founder of Precipio, a company with a liquid biopsy technology, took time to talk to BioSpace about the company and the economics of liquid biopsies.
• 

  Karius Liquid Biopsy Accurately Detects Invasive Fungal Infections

  7/20/2018

  Some diagnostics testing for infectious diseases can be quite invasive and uncomfortable for a patient. Now though, a new form of test is available that can mitigate the need for those invasive tests.

• Journal of Diagnostic Microbiology and Infectious Disease Publishes New Clinical Study Data on Karius Test

  7/17/2018

  Study Confirms Liquid Biopsy for Infectious Diseases Accurately Detects Invasive Fungal Infections

• Karius Announces Launch of Quantitative, Broad-Based Infectious Disease Diagnostic Test Using Microbial Cell-Free DNA Test Detects and Quantifies DNA from Bacteria, Viruses and Fungi in a Single Blood Sample

  5/9/2018

  Karius announced today that the new version of its proprietary Karius Test can now quantify the abundance of pathogens detected.

• 

  6 Blood Testing Startups Hoping to be The Next Theranos - The Good Version

  1/12/2018

  A look at 6 up and coming blood-testing startups.

• New Data Show Karius Test Improves Pathogen Detection In Challenging Patient Populations

  10/4/2017

• Karius Nabs $50 Million for Technology Enabling Broad and Rapid Detection of Infectious Diseases

  8/8/2017